# Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients

> **NCT05388435** · PHASE1,PHASE2 · TERMINATED · sponsor: **SK Life Science, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** SKL27969

## Key facts

- **NCT ID:** NCT05388435
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-12
- **Primary completion:** 2024-03-01
- **Final completion:** 2024-03-01
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The study has been terminated based on portfolio prioritization. No safety trends or issues were identified at any dose level.
- **Last updated:** 2025-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05388435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05388435, "Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05388435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*